表紙
市場調查報告書

5-羥色胺(血清素)受體7:開發中產品分析

5-Hydroxytryptamine Receptor 7 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 520774
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
5-羥色胺(血清素)受體7:開發中產品分析 5-Hydroxytryptamine Receptor 7 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 75 Pages
簡介

本報告提供以5-羥色胺(血清素)受體7為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

5-羥色胺(血清素)受體7;概要

5-羥色胺(血清素)受體7;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Adamed Sp z oo
  • Astellas Pharma Inc
  • Braeburn Pharmaceuticals Inc
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Reviva Pharmaceuticals Inc
  • 大日本住友製藥

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2060TDB

Summary

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT). The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders.

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 2, 3, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Genetic Disorders, Male Health, Respiratory and Women's Health which include indications Bipolar Disorder (Manic Depression), Schizophrenia, Autism, Cognitive Disorders, Psychiatric Disorders, Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Crohn's Disease (Regional Enteritis), Female Sexual Dysfunction, Fragile X Syndrome, Generalized Anxiety Disorder (GAD), Idiopathic Pulmonary Fibrosis, Inflammatory Pain, Major Depressive Disorder, Male Sexual Dysfunction, Neuropathic Pain (Neuralgia), Pervasive Developmental Disorder (PDD), Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Sleep Disorders, Social Anxiety Disorder (SAD/Social Phobia) and Ulcerative Colitis.

The latest report 5-Hydroxytryptamine Receptor 7 - Pipeline Review, H2 2019, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
  • The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Overview
  • 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Companies Involved in Therapeutics Development
  • Adamed Sp zoo
  • Avineuro Pharmaceuticals Inc
  • Daya Drug Discoveries Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • Lb Pharmaceuticals Inc
  • Praeventix LLC
  • Reviva Pharmaceuticals Inc
  • Seropeutics LLC
  • Sumitomo Dainippon Pharma Co Ltd
  • 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Drug Profiles
  • ADN-1184 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ADN-3662 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVN-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • brilaroxazine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DDD-028 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JNJ-18038683 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LB-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lurasidone hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SERx-519 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize 5 HT7 Receptors for Crohn's Disease and Ulcerative Colitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Target 5-HT7R for Sleep Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vortioxetine hydrobromide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products
  • 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Discontinued Products
  • 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 09, 2019: ChemRar Group of Companies announces the successful completion of the second phase of clinical trials of an innovative drug for the treatment of generalized anxiety disorder
  • Sep 20, 2019: Takeda and Lundbeck's Trintellix approved in Japan for depression
  • Sep 03, 2019: Sumitomo Dainippon Pharma Announces the Launch of Atypical Antipsychotic LATUDA in China
  • Jul 31, 2019: Sumitomo Dainippon Pharma submits New Drug Application for approval of Manufacturing and Marketing for Lurasidone in Japan for the treatment of Schizophrenia and Bipolar Depression
  • Jun 03, 2019: Reviva Pharmaceuticals announces successful completion of pre-IND meeting with FDA on Brilaroxazine for the treatment of idiopathic pulmonary fibrosis
  • May 02, 2019: Sunovion highlights data on LATUDA at the 2019 American Psychiatric Association Annual Meeting
  • Jan 29, 2019: Sumitomo Dainippon Pharma announces the approval of atypical antipsychotic Latuda (lurasidone HCl) for the treatment of patients with schizophrenia in China
  • Jan 10, 2019: Sumitomo Dainippon Pharma announces positive topline results from a phase III clinical study (JEWEL Study) of Lurasidone, an atypical antipsychotic agent, in the treatment of patients with schizophrenia
  • Dec 05, 2018: Sumitomo Dainippon Pharma announces resolution of consolidated patent infringement lawsuit regarding ANDAs for LATUDA in the U.S.
  • Nov 27, 2018: Sumitomo Dainippon Pharma announces resolution of disputes under consolidated patent infringement lawsuit regarding ANDAs for LATUDA in the U.S.
  • Oct 22, 2018: U.S. Food and Drug Administration approves expansion of Trintellix (vortioxetine) label
  • Oct 22, 2018: New Data Added to TRINTELLIX (vortioxetine) Labeling Demonstrated Superiority Over Escitalopram in Improving SSRI-Induced Sexual Dysfunction in Patients with Major Depressive Disorder
  • Sep 28, 2018: Takeda and Lundbeck submit New Drug Application (NDA) for vortioxetine in Japan for the treatment of Major Depressive Disorder (MDD)
  • Jun 08, 2018: Positive clinical phase III results of vortioxetine in Japanese adults with Major Depressive Disorder
  • May 02, 2018: TRINTELLIX (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD)
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Adamed Sp zoo, H2 2019
  • Pipeline by Avineuro Pharmaceuticals Inc, H2 2019
  • Pipeline by Daya Drug Discoveries Inc, H2 2019
  • Pipeline by H. Lundbeck AS, H2 2019
  • Pipeline by Johnson & Johnson, H2 2019
  • Pipeline by Lb Pharmaceuticals Inc, H2 2019
  • Pipeline by Praeventix LLC, H2 2019
  • Pipeline by Reviva Pharmaceuticals Inc, H2 2019
  • Pipeline by Seropeutics LLC, H2 2019
  • Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
Back to Top